In:
Cancer, Wiley, Vol. 127, No. 18 ( 2021-09-15), p. 3381-3389
Abstract:
The combination of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) with ofatumumab results in better outcomes than hyper‐CVAD with rituximab in patients with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia. Ofatumumab may be an optimal anti‐CD20 monoclonal antibody in this setting.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v127.18
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1